Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar:182:114045.
doi: 10.1016/j.addr.2021.114045. Epub 2021 Nov 9.

MicroRNAs and their delivery in diabetic fibrosis

Alexa Wonnacott  1 , Laura Denby  2 , Richard J M Coward  3 , Donald J Fraser  1 , Timothy Bowen  4
Affiliations
Review

MicroRNAs and their delivery in diabetic fibrosis

Alexa Wonnacott et al. Adv Drug Deliv Rev. 2022 Mar.

Abstract

The global prevalence of diabetes mellitus was estimated to be 463 million people in 2019 and is predicted to rise to 700 million by 2045. The associated financial and societal costs of this burgeoning epidemic demand an understanding of the pathology of this disease, and its complications, that will inform treatment to enable improved patient outcomes. Nearly two decades after the sequencing of the human genome, the significance of noncoding RNA expression is still being assessed. The family of functional noncoding RNAs known as microRNAs regulates the expression of most genes encoded by the human genome. Altered microRNA expression profiles have been observed both in diabetes and in diabetic complications. These transcripts therefore have significant potential and novelty as targets for therapy, therapeutic agents and biomarkers.

Keywords: Chronic kidney disease; Diabetes; Fibrosis; Nanotechnology; Noncoding RNA; microRNA; microRNA-based therapeutics.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: TB and DF are inventors for patent WO/2017/129977 Chronic Kidney Disease Diagnostic. LD is the recipient of PhD studentship co-funding from Regulus Therapeutics and GSK.

Publication types

MeSH terms